Date: 2016-04-20
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: Curis (USA - MA) Aurigene (India)
Product: CA-170
Action
mechanism: immune chekpoint antagonist. CA-170 is orally-available small molecule antagonist of programmed death ligand-1 (PD-L1) in the immuno-oncology field. Curis has exclusive licenses to CA-170 under a collaboration agreement with Aurigene established in 2015.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 20, 2016, Curis and its collaborator, Aurigene, presented data on CA-170 (previously AUPM-170), a first-in-class oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) at the Annual Meeting of American Association of Cancer Research (AACR) in New Orleans. The Aurigene presentation "Oral immune antagonist targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy" provided data outlining the novel approach of identification and characterization of oral antagonists of immune checkpoint proteins. The lead IND-ready molecule, CA-170, targets PD-L1 and VISTA and has an optimized pharmacologic and safety profile required for human testing.